In the latest cancer treatment innovations that have sprung up over the last decade, oncolytic viruses have been viewed as tools for directly killing cancer cells. Since the approval of talimogene laherparepvec (Imlygic®) or otherwise known as T-Vec, Beacon has seen a new wave of oncolytic virus development emerging from academic research and into the clinic.

Join Virogin Biotech Limited, Massachusetts General Hospital and Beacon Targeted Therapies in this webinar as we take a closer look at what this novel landscape looks like, what trends are emerging, and the key insights and insights from industry leaders in the field.